Cargando…

Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia

PURPOSE: The aim of this work was to study the influence of solidification of meloxicam (Mel) containing nanosuspension (nanoMel) on the physical stability and drug bioavailability of the products. The nanoMel sample had poly(vinyl alcohol) (PVA) as a protective polymer, but no surfactant as a furth...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartos, Csaba, Ambrus, Rita, Katona, Gábor, Sovány, Tamás, Gáspár, Róbert, Márki, Árpád, Ducza, Eszter, Ivanov, Anita, Tömösi, Ferenc, Janáky, Tamás, Szabó-Révész, Piroska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886534/
https://www.ncbi.nlm.nih.gov/pubmed/31819372
http://dx.doi.org/10.2147/DDDT.S220876
_version_ 1783474889856909312
author Bartos, Csaba
Ambrus, Rita
Katona, Gábor
Sovány, Tamás
Gáspár, Róbert
Márki, Árpád
Ducza, Eszter
Ivanov, Anita
Tömösi, Ferenc
Janáky, Tamás
Szabó-Révész, Piroska
author_facet Bartos, Csaba
Ambrus, Rita
Katona, Gábor
Sovány, Tamás
Gáspár, Róbert
Márki, Árpád
Ducza, Eszter
Ivanov, Anita
Tömösi, Ferenc
Janáky, Tamás
Szabó-Révész, Piroska
author_sort Bartos, Csaba
collection PubMed
description PURPOSE: The aim of this work was to study the influence of solidification of meloxicam (Mel) containing nanosuspension (nanoMel) on the physical stability and drug bioavailability of the products. The nanoMel sample had poly(vinyl alcohol) (PVA) as a protective polymer, but no surfactant as a further stabilizing agent because the final aim was to produce surfactant-free solid phase products as well. METHODS: The solidified samples produced by fluidization and lyophilization (fluidMel, lyoMel) were examined for particle size, crystallinity, and in vitro release of Mel compared to similar parameters of nanoMel. The products were subjected to an animal experiment using per oral administration to verify their bioavailability. RESULTS: Mel containing (1%) nanoMel sample was produced by wet milling process using an optimized amount of PVA (0.5%) which resulted in 130 nm as mean particle size and a significant reduction in the degree of crystallinity (13.43%) of Mel. The fluidization technique using microcrystalline cellulose (MCC) as carrier resulted in a quick conversion and no significant change in the critical product parameters. The process of lyophilization required a longer operation time, which resulted in the amorphization of the crystalline carrier (trehalose) and the recrystallization of Mel increased its particle size and crystallinity. The fluidMel and lyoMel samples had nearly five-fold higher relative bioavailability than nanoMel application by oral administration. The correlation between in vitro and in vivo studies showed that the fixed Mel nanoparticles on the surface of solid carriers (MCC, trehalose) in both the artificial gastric juice and the stomach of the animals rapidly reached saturation concentration leading to faster dissolution and rapid absorption. CONCLUSION: The solidification of the nanosuspension not only increased the stability of the Mel nanoparticles but also allowed the preparation of surfactant-free compositions with excellent bioavailability which may be an important consideration for certain groups of patients to achieve rapid analgesia.
format Online
Article
Text
id pubmed-6886534
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68865342019-12-09 Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia Bartos, Csaba Ambrus, Rita Katona, Gábor Sovány, Tamás Gáspár, Róbert Márki, Árpád Ducza, Eszter Ivanov, Anita Tömösi, Ferenc Janáky, Tamás Szabó-Révész, Piroska Drug Des Devel Ther Original Research PURPOSE: The aim of this work was to study the influence of solidification of meloxicam (Mel) containing nanosuspension (nanoMel) on the physical stability and drug bioavailability of the products. The nanoMel sample had poly(vinyl alcohol) (PVA) as a protective polymer, but no surfactant as a further stabilizing agent because the final aim was to produce surfactant-free solid phase products as well. METHODS: The solidified samples produced by fluidization and lyophilization (fluidMel, lyoMel) were examined for particle size, crystallinity, and in vitro release of Mel compared to similar parameters of nanoMel. The products were subjected to an animal experiment using per oral administration to verify their bioavailability. RESULTS: Mel containing (1%) nanoMel sample was produced by wet milling process using an optimized amount of PVA (0.5%) which resulted in 130 nm as mean particle size and a significant reduction in the degree of crystallinity (13.43%) of Mel. The fluidization technique using microcrystalline cellulose (MCC) as carrier resulted in a quick conversion and no significant change in the critical product parameters. The process of lyophilization required a longer operation time, which resulted in the amorphization of the crystalline carrier (trehalose) and the recrystallization of Mel increased its particle size and crystallinity. The fluidMel and lyoMel samples had nearly five-fold higher relative bioavailability than nanoMel application by oral administration. The correlation between in vitro and in vivo studies showed that the fixed Mel nanoparticles on the surface of solid carriers (MCC, trehalose) in both the artificial gastric juice and the stomach of the animals rapidly reached saturation concentration leading to faster dissolution and rapid absorption. CONCLUSION: The solidification of the nanosuspension not only increased the stability of the Mel nanoparticles but also allowed the preparation of surfactant-free compositions with excellent bioavailability which may be an important consideration for certain groups of patients to achieve rapid analgesia. Dove 2019-11-28 /pmc/articles/PMC6886534/ /pubmed/31819372 http://dx.doi.org/10.2147/DDDT.S220876 Text en © 2019 Bartos et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Bartos, Csaba
Ambrus, Rita
Katona, Gábor
Sovány, Tamás
Gáspár, Róbert
Márki, Árpád
Ducza, Eszter
Ivanov, Anita
Tömösi, Ferenc
Janáky, Tamás
Szabó-Révész, Piroska
Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia
title Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia
title_full Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia
title_fullStr Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia
title_full_unstemmed Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia
title_short Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia
title_sort transformation of meloxicam containing nanosuspension into surfactant-free solid compositions to increase the product stability and drug bioavailability for rapid analgesia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886534/
https://www.ncbi.nlm.nih.gov/pubmed/31819372
http://dx.doi.org/10.2147/DDDT.S220876
work_keys_str_mv AT bartoscsaba transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia
AT ambrusrita transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia
AT katonagabor transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia
AT sovanytamas transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia
AT gasparrobert transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia
AT markiarpad transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia
AT duczaeszter transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia
AT ivanovanita transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia
AT tomosiferenc transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia
AT janakytamas transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia
AT szaboreveszpiroska transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia